These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Targeted alpha-therapy for control of micrometastatic prostate cancer. Li Y; Russell PJ; Allen BJ Expert Rev Anticancer Ther; 2004 Jun; 4(3):459-68. PubMed ID: 15161444 [TBL] [Abstract][Full Text] [Related]
23. Intraperitoneal alpha-particle radioimmunotherapy of ovarian cancer patients: pharmacokinetics and dosimetry of (211)At-MX35 F(ab')2--a phase I study. Andersson H; Cederkrantz E; Bäck T; Divgi C; Elgqvist J; Himmelman J; Horvath G; Jacobsson L; Jensen H; Lindegren S; Palm S; Hultborn R J Nucl Med; 2009 Jul; 50(7):1153-60. PubMed ID: 19525452 [TBL] [Abstract][Full Text] [Related]
24. Targeted alpha therapy: part I. Elgqvist J Curr Radiopharm; 2011 Jul; 4(3):176. PubMed ID: 22201706 [TBL] [Abstract][Full Text] [Related]
25. Radioimmunoconjugates in acute leukemia treatment: the future is radiant. Kotzerke J; Bunjes D; Scheinberg DA Bone Marrow Transplant; 2005 Dec; 36(12):1021-6. PubMed ID: 16247432 [TBL] [Abstract][Full Text] [Related]
28. Status of radioimmunotherapy in the new millennium. Imam SK Cancer Biother Radiopharm; 2001 Jun; 16(3):237-56. PubMed ID: 11471488 [TBL] [Abstract][Full Text] [Related]
29. Radioimmunotherapy of experimental human metastatic melanoma with melanin-binding antibodies and in combination with dacarbazine. Revskaya E; Jongco AM; Sellers RS; Howell RC; Koba W; Guimaraes AJ; Nosanchuk JD; Casadevall A; Dadachova E Clin Cancer Res; 2009 Apr; 15(7):2373-9. PubMed ID: 19293257 [TBL] [Abstract][Full Text] [Related]
31. Radioimmunotherapy of cancer with high linear energy transfer (LET) radiation delivered by radionuclides emitting α-particles or Auger electrons. Aghevlian S; Boyle AJ; Reilly RM Adv Drug Deliv Rev; 2017 Jan; 109():102-118. PubMed ID: 26705852 [TBL] [Abstract][Full Text] [Related]
33. Emerging trends for radioimmunotherapy in solid tumors. Jain M; Gupta S; Kaur S; Ponnusamy MP; Batra SK Cancer Biother Radiopharm; 2013 Nov; 28(9):639-50. PubMed ID: 23844555 [TBL] [Abstract][Full Text] [Related]
34. Radioimmunotherapy with α-particle-emitting radionuclides. Seidl C Immunotherapy; 2014; 6(4):431-58. PubMed ID: 24815783 [TBL] [Abstract][Full Text] [Related]
35. Intravesical alpha-radioimmunotherapy with 213Bi-anti-EGFR-mAb defeats human bladder carcinoma in xenografted nude mice. Pfost B; Seidl C; Autenrieth M; Saur D; Bruchertseifer F; Morgenstern A; Schwaiger M; Senekowitsch-Schmidtke R J Nucl Med; 2009 Oct; 50(10):1700-8. PubMed ID: 19793735 [TBL] [Abstract][Full Text] [Related]
36. [Monoclonal antibodies. General approach and radioimmunotherapy]. Sousa O; Vieira E Acta Med Port; 1998 Apr; 11(4):337-47. PubMed ID: 9644845 [TBL] [Abstract][Full Text] [Related]
37. Radioimmunotherapy for delivery of cytotoxic radioisotopes: current status and challenges. Martins CD; Kramer-Marek G; Oyen WJG Expert Opin Drug Deliv; 2018 Feb; 15(2):185-196. PubMed ID: 28893110 [TBL] [Abstract][Full Text] [Related]
38. [Systemic radiotherapy using monoclonal antibodies. Options and problems]. Sautter-Bihl ML; Wannenmacher M; Bihl H Strahlenther Onkol; 1993 Jun; 169(6):358-65. PubMed ID: 8316939 [TBL] [Abstract][Full Text] [Related]
39. Development of anti-MUC1 di-scFvs for molecular targeting of epithelial cancers, such as breast and prostate cancers. Albrecht H; Denardo GL; Denardo SJ Q J Nucl Med Mol Imaging; 2007 Dec; 51(4):304-13. PubMed ID: 17464275 [TBL] [Abstract][Full Text] [Related]